Related Experiment Video
Updated: May 16, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Patient preferences for hepatitis B therapy
Seng Gee Lim1, Myat Oo Aung, Stephanie W M Chung
1Department of Gastroenterology and Hepatology, National University Health System, Singapore. mdclimsg@nus.edu.sg.
Insights
Patient preferences significantly influence chronic hepatitis B (CHB) treatment choices. Efficacy and oral, once-daily dosing are key, with entecavir being the preferred drug among surveyed patients.
Area of Science:
- Hepatology
- Patient-centered care
- Pharmacoeconomics
Background:
- Limited understanding of patient preferences in chronic hepatitis B (CHB) treatment selection.
- Patient preferences impact therapeutic choices and long-term health outcomes for CHB patients.
Purpose of the Study:
- To investigate patient preferences regarding CHB treatment.
- To identify key factors influencing patient selection of CHB therapies.
Main Methods:
- Questionnaire-based survey of CHB patients at a follow-up clinic.
- Assessed knowledge, preferred administration route/frequency, duration, cost, adverse events, resistance, efficacy, and doctor discussions.
- Patients ranked priorities and selected preferred therapy after reviewing drug profiles.
Main Results:
- Lamivudine was the most recognized drug; entecavir was the preferred therapy.
- Most patients favored oral, once-daily dosing with a fixed treatment duration.
- Drug efficacy was the primary selection factor; patients expected cure and were willing to pay up to $10 daily.
Conclusions:
- Patient preferences are crucial for evaluating and selecting CHB treatments.
- Aligning treatment choices with patient preferences can improve adherence and outcomes.
Background:
Little is known about patient preferences for selection of chronic hepatitis B (CHB) treatment. This issue is important as it affects the therapeutic choices available for patients and, in the long term, the health of CHB patients.
Methods:
The study was a questionnaire-led survey directed at patients attending a CHB follow-up clinic. Patients were asked questions regarding their knowledge on CHB treatment, preferred route and frequency of administration, duration of treatment, cost, adverse events, viral resistance, efficacy and whether treatment options were discussed with doctors. Patients were also asked to rank their priorities when selecting treatment for CHB. In addition, a summary of the profile of current agents was shown to patients who were then asked to select their preferred therapy. Finally, patients were asked questions regarding their willingness to pay for CHB treatment and expectations of treatment. Questionnaires were self-administered and statistical analysis was performed using SPSS (version 10.0).
Results:
Lamivudine was the best-known drug among patients. Only 30% of patients were treatment-naive. Most patients preferred oral therapy with once-daily dosing and a fixed duration of treatment. Drug efficacy was considered the most important factor in drug selection. When shown the profile of the different drugs available for the treatment of CHB, entecavir was the preferred choice of therapy. The majority of patients were willing to spend no more than S$10 (USD 8) daily for therapy with expectation of cure for their disease. Overall, 92% of patients would follow doctor's recommendations.
Conclusions:
Patients' preferences are important in evaluating drug selection for CHB.
More Related Videos
Related Concept Videos
01:25Hepatitis
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:28Viral Hepatitis I: Introduction
01:30Inhibitors of Viral Protein Synthesis
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow